Lilly advances amylin-based obesity combo to phase 3, tests tolerability amid Korea race (Chosun Biz) - Oct 26, 2026 - "According to the U.S. clinical information site ClinicalTrials, Lilly recently registered two global phase 3 trials of EloraTZP (AMPLIFY-1, AMPLIFY-2). The large studies will enroll a total of 3,115 patients, stratified by the presence of type 2 diabetes, and both aim to complete in Nov. 2029."
Trial status • Obesity • Type 2 Diabetes Mellitus
|